Humira (adalimumab) Injection, Solution For Subcutaneous Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

Summary View

 

Sections Modified	Summary of Changes to Contraindications and Warnings
WARNINGS AND PRECAUTIONS Malignancies ADVERSE REACTIONS Immunogenicity Plaque Psoriasis Clinical Studies PATIENT COUNSELING INFORMATION Medication Guide MEDICATION GUIDE (new)	WARNINGS AND PRECAUTIONS See highlighted text for labeling revisions.